118 Results

People

  1. Motzer
    Motzer
  2. Abou-Alfa
    Abou-Alfa
  3. Drilon
    Drilon
  4. Morris
    Morris
  5. Scher
    Scher
  6. Ladanyi
    Ladanyi
  7. Voss
    Voss
  8. Carlo
    Carlo
  9. Feldman
    Feldman
  10. Kotecha
    Kotecha

Groups

  1. Department of Medicine (105)
  2. Solid Tumor Oncology Division (97)
  3. Genitourinary Oncology Service (55)
  4. Thoracic Oncology (19)
  5. Gastrointestinal Oncology Service (18)
  6. GSK Faculty (14)
  7. Sloan Kettering Institute Postdocs (14)
  8. Radiology, Department of (13)
  9. Weinberg Fellows (12)
  10. Department of Pathology and Laboratory Medicine (11)
  1. "cabozantinib"
Formats
  1. Journal Article (88)
  2. Review (18)
  3. Editorial (4)
  4. Research Letter (3)
  5. Correspondence (2)
  6. Meeting Abstract (2)
  7. Guidelines (1)
Groups
  1. Department of Medicine (105)
  2. Solid Tumor Oncology Division (97)
  3. Genitourinary Oncology Service (55)
  4. Thoracic Oncology (19)
  5. Gastrointestinal Oncology Service (18)
  6. GSK Faculty (14)

More Groups

People
  1. Robert Motzer (25)
  2. Alexander Drilon (16)
  3. Ghassan Abou-Alfa (16)
  4. Michael Morris (11)
  5. Howard Scher (8)
  6. Marc Ladanyi (7)

More People

Years
  1. 2025 (8)
  2. 2024 (11)
  3. 2023 (12)
  4. 2022 (15)
  5. 2021 (7)
  6. 2020 (18)

More Years

Publications
  1. European Urology (8)
  2. Clinical Cancer Research (6)
  3. European Journal of Cancer (6)
  4. New England Journal of Medicine (6)
  5. Journal of Thoracic Oncology (5)
  6. Current Treatment Options in Oncology (4)

More Publications

Publishers
  1. Elsevier Inc. (23)
  2. Elsevier Science, Inc. (14)
  3. American Association for Cancer Research (8)
  4. Oxford University Press (7)
  5. Massachusetts Medical Society (6)
  6. Springer (5)

More Publishers

Results (118)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
    Journal Article

    Donskov, F.; Motzer, R. J.; Voog, E.; Hovey, E.; Grùˆllich, C.; Nott, L. M.; Cuff, K.; Gil, T.; Jensen, N. V.; Chevreau, C.; more...
    European Journal of Cancer (2020)

    Fulltext@MSK | Save
  • A phase 2 trial of cabozantinib in ROS1-rearranged lung adenocarcinoma
    Meeting Abstract

    Guo, R.; Preeshagul, I.; Schoenfeld, A.; McCarthy, C.; Makhnin, A.; Plodkowski, A.; Ginsberg, M.; Davare, M.; Delasos, L.; Somwar, R.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Cabozantinib versus sunitinib for untreated patients with advanced renal cell carcinoma of intermediate or poor risk: Subgroup analysis of the Alliance A031203 CABOSUN trial
    Journal Article

    George, D. J.; Hessel, C.; Halabi, S.; Michaelson, M. D.; Hahn, O.; Walsh, M.; Picus, J.; Small, E. J.; Dakhil, S.; Feldman, D. R.; more...
    The Oncologist (2019)

    Fulltext@MSK | Save
  • PD-L1 expression and clinical outcomes to cabozantinib, everolimus, and sunitinib in patients with metastatic renal cell carcinoma: Analysis of the randomized clinical trials METEOR and CABOSUN
    Journal Article

    Flaifel, A.; Xie, W.; Braun, D. A.; Ficial, M.; Bakouny, Z.; Nassar, A. H.; Jennings, R. B.; Escudier, B.; George, D. J.; Motzer, R. J.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • A prospective study of circulating tumor DNA to guide matched targeted therapy in lung cancers
    Journal Article

    Sabari, J. K.; Offin, M.; Stephens, D.; Ni, A.; Lee, A.; Pavlakis, N.; Clarke, S.; Diakos, C. I.; Datta, S.; Tandon, N.; more...
    JNCI: Journal of the National Cancer Institute (2019)

    Fulltext@MSK | Save
  • Cabozantinib versus mitoxantrone-prednisone in symptomatic metastatic castration-resistant prostate cancer: A randomized phase 3 trial with a primary pain endpoint
    Journal Article

    Basch, E. M.; Scholz, M.; de Bono, J. S.; Vogelzang, N.; de Souza, P.; Marx, G.; Vaishampayan, U.; George, S.; Schwarz, J. K.; Antonarakis, E. S.; more...
    European Urology (2019)

    Fulltext@MSK | Save
  • Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors
    Journal Article

    Shah, A. Y.; Kotecha, R. R.; Lemke, E. A.; Chandramohan, A.; Chaim, J. L.; Msaouel, P.; Xiao, L.; Gao, J.; Campbell, M. T.; Zurita, A. J.; more...
    European Journal of Cancer (2019)

    Fulltext@MSK | Save
  • A well organised effort to metastatic non-clear-cell renal cell carcinoma
    Editorial

    Russo, P.
    Lancet Oncology (2019)

    Fulltext@MSK | Save
  • A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study
    Journal Article

    Matulonis, U. A.; Sill, M. W.; Makker, V.; Mutch, D. G.; Carlson, J. W.; Darus, C. J.; Mannel, R. S.; Bender, D. P.; Crane, E. K.; Aghajanian, C.
    Gynecologic Oncology (2019)

    Fulltext@MSK | Save
  • Systemic therapy for advanced hepatocellular carcinoma in an evolving landscape
    Review

    Mody, K.; Abou-Alfa, G. K.
    Current Treatment Options in Oncology (2019)

    Fulltext@MSK | Save